Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04186520 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04186520 · ClinicalTrials.gov record · last posted 2026-02-23

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

StatusRecruiting
PhasePhase 1/2
Started2020-05-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

Amendment record 11 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 11 times since 2019-12-02; most recent amendment 2026-02-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-05-26
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT04186520
Lead Sponsor Medical College of Wisconsin
Conditions Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Enrollment 100 participants
Start Date 2020-05-18
Primary Completion 2027-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-23